FDA Approves Epcoritamab for r/r B-Cell Lymphoma FDA Approves Epcoritamab for r/r B-Cell Lymphoma
Epcoritamab is the first subcutaneous bispecific antibody approved for the indication.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 19, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
YouTuber Hank Green Reveals Cancer Diagnosis, Will Miss VidCon as He Undergoes Treatment
Hank Green, the popular YouTube video creator and VidCon co-founder, announced Friday that he has been diagnosed with cancer. In a video posted Friday on YouTube, Green said he was diagnosed with Hodgkin’s lymphoma, a type of cancer of the lymphatic system (which is part of the body’s immune…#hankgreen #vidcon #hodgkin #johngreen #faultinourstars #alaska #anaheim #vidconanaheim #paramountglobal #vlogbrothers (Source: Reuters: Health)
Source: Reuters: Health - May 19, 2023 Category: Consumer Health News Source Type: news
FDA approves treatment for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
FDA has approved Epkinly (epcoritamab-bysp) injection for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B ‑cell lymphoma after two or more lines of systemic the (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 19, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Bispecific Antibody Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
(MedPage Today) -- Credit: CoRus13
The FDA granted accelerated approval to epcoritamab (Epkinly) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B‑cell lymphoma on Friday.... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 19, 2023 Category: American Health Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
DLBCL: Major New Treatment Breakthroughs DLBCL: Major New Treatment Breakthroughs
Recent significant breakthroughs for diffuse large B-cell lymphoma (DLBCL) have come through the use of CAR T-cell and immunotherapies and the FDA approval of polatuzumab for frontline DLBCL.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas
(MedPage Today) -- Allogeneic hematopoietic stem cell transplantation (HSCT) was associated with significant improvements in progression-free survival (PFS) in patients with advanced cutaneous T-cell lymphomas (CTCLs), according to the propensity... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 11, 2023 Category: Dermatology Source Type: news
Small Increase in Lymphoma Risk Seen With Crohn Disease, Ulcerative Colitis
WEDNESDAY, May 10, 2023 -- Crohn disease (CD) and ulcerative colitis (UC) are associated with a slightly increased risk for lymphoma, according to a study published online April 13 in Clinical Gastroenterology and Hepatology.
Ola Olén M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 10, 2023 Category: Pharmaceuticals Source Type: news
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Results Confirm and Extend Response Results from Phase 3 FLASH Study
PRINCETON, N.J., May 4, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ... Biopharmaceuticals, Oncology Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 4, 2023 Category: Pharmaceuticals Source Type: news
Building Bridges in CAR-T for Follicular Lymphoma Building Bridges in CAR-T for Follicular Lymphoma
Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
B-Cell Stimulating Factors Tied to Lymphoma in Sjogren's
(MedPage Today) -- Genetic blood tests indicated that Bruton's tyrosine kinase (BTK) and a cytokine called APRIL were overexpressed in patients with primary Sjögren's syndrome who subsequently developed lymphoma, French researchers reported... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 2, 2023 Category: Hematology Source Type: news
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
HORSHAM, Pa., May 2, 2023 – Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. These investigational CD20-directed autologous CAR-Ts have demonstrated promising overall and complete response rates in Phase 1 studies in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) in China, with the m...
Source: Johnson and Johnson - May 2, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Cancer breakthrough as promising compound found that slows lymphoma growth
The prospective drug works by enlisting cellular disposal systems to destroy a protein that drives the growth of B-cell lymphoma. (Source: Daily Express - Health)
Source: Daily Express - Health - April 27, 2023 Category: Consumer Health News Source Type: news
Episode 5: Key Topics in the Pathology of Mantle Cell Lymphoma Episode 5: Key Topics in the Pathology of Mantle Cell Lymphoma
Drs Peter Martin and Eric Hsi have a thought-provoking discussion on key topics in the pathology of mantle cell lymphoma, including biopsies, diagnostic markers, and what the future holds for treatment.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
PET/CT reveals different reactions to COVID-19 vaccines
PET/CT imaging shows that COVID-19 mRNA vaccines appear to cause higher rate...Read more on AuntMinnie.comRelated Reading:
PET tracer uptake related to COVID-19 vaccines detected in lymphoma patients
F-18 FDG lymph node uptake assessed in vaccinated COVID-19 patients
Women benefit from scheduling mammograms around COVID vaccine
Ultrasound finds swollen glands on patients after COVID-19 vaccine (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 27, 2023 Category: Radiology Source Type: news
